. 2025 Aug 23;15:31032. doi: 10.1038/s41598-025-15430-w

Table 1.

Substance treatment details.

Compound	Rasagiline	Safinamide	Flecainide	Phenytoin
Administration form	Oral administration	Oral administration	Subcutaneous injection	Subcutaneous injection
Concentration	5 mg/kg/bw	8 mg/kg/bw	30 mg/kg bw	50 mg/kg bw
Mode of action	Selective MAO-B inhibition	Reversible MAO-B inhibition Sodium and calcium channel blocking Glutamate release inhibition Dopamine and serotonin reuptake inhibition	Selective NaV1.5 sodium channel blocker	Unselective NaV1.1, NaV1.2, NaV1.3, NaV1.5 and NaV1.6 sodium channel blocker
Treatment interval	Daily	Daily	Daily	3 times/week
Treatment start	Directly p.i	Directly p.i	Directly p.i	Directly p.i
CAS Corresponding treatment reference	161735-79-1 (Sigma Aldrich) ^14,15	202825-46-5 (Sigma Aldrich) ¹⁶	54143-56-5 (Sigma Aldrich) ¹³	630-93-3 (Sigma Aldrich) ¹¹